A Phase 1 Study of ABT-806 in Subjects With Advanced Solid Tumor Types Likely to Either Overexpress Wild-Type Epidermal Growth Factor Receptor (EGFR) or to Express Variant III Mutant EGFR.

Trial Profile

A Phase 1 Study of ABT-806 in Subjects With Advanced Solid Tumor Types Likely to Either Overexpress Wild-Type Epidermal Growth Factor Receptor (EGFR) or to Express Variant III Mutant EGFR.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2016

At a glance

  • Drugs Depatuxizumab (Primary)
  • Indications Colorectal cancer; Glioblastoma; Head and neck cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 05 Jun 2016 Results from an expansion cohort of one arm of this trial were presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), according to an Abbvie media release.
    • 05 Jun 2016 Results from an expansion cohort of one arm published in a Abbvie media release.
    • 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top